The Mark Foundation for Cancer Research
@themarkfdn.bsky.social
Partnering with scientists to accelerate transformation in cancer research.
Since 2018, the ELA program has awarded over $40M to spark innovation. This year, we are also proud to partner with The Bakewell Foundation to support Jeremy Borniger’s unconventional and bold research. 🤝
January 14, 2026 at 11:16 AM
Since 2018, the ELA program has awarded over $40M to spark innovation. This year, we are also proud to partner with The Bakewell Foundation to support Jeremy Borniger’s unconventional and bold research. 🤝
Christopher Johnston is engineering human-derived bacteria to act as "cellular therapies," infiltrating solid tumors to deliver medicine directly into the most treatment-resistant environments. 🧫 @mdanderson.bsky.social
January 14, 2026 at 11:16 AM
Christopher Johnston is engineering human-derived bacteria to act as "cellular therapies," infiltrating solid tumors to deliver medicine directly into the most treatment-resistant environments. 🧫 @mdanderson.bsky.social
Mariella Filbin is exploring how aggressive childhood brain tumors hijack normal brain activity to repair their own DNA. This research aims to break through radiation resistance in diffuse midline gliomas. 🧠 @danafarbernews.bsky.social
January 14, 2026 at 11:16 AM
Mariella Filbin is exploring how aggressive childhood brain tumors hijack normal brain activity to repair their own DNA. This research aims to break through radiation resistance in diffuse midline gliomas. 🧠 @danafarbernews.bsky.social
Lucas Farnung will use "visual biochemistry" at atomic resolution to see exactly how errors in DNA replication drive cancer. This high-def view will reveal brand-new targets for drug development. 🔬 @harvardmed.bsky.social @lucas.farnunglab.com
January 14, 2026 at 11:16 AM
Lucas Farnung will use "visual biochemistry" at atomic resolution to see exactly how errors in DNA replication drive cancer. This high-def view will reveal brand-new targets for drug development. 🔬 @harvardmed.bsky.social @lucas.farnunglab.com
Iok In Christine Chio is developing non-invasive imaging to detect pancreatic cancer in its earliest stages by tracking how the disease redistributes iron throughout the body. 🔍 @columbiacancer.bsky.social @columbiamed.bsky.social
January 14, 2026 at 11:16 AM
Iok In Christine Chio is developing non-invasive imaging to detect pancreatic cancer in its earliest stages by tracking how the disease redistributes iron throughout the body. 🔍 @columbiacancer.bsky.social @columbiamed.bsky.social
Jeremy Borniger, The Bakewell Foundation Emerging Leader Awardee, will investigate "synthetic torpor"—inducing a hibernation-like state to globally suppress metabolism. The goal? Starve tumors while sparing healthy tissue. ❄️🧬 @cshlnews.bsky.social
January 14, 2026 at 11:16 AM
Jeremy Borniger, The Bakewell Foundation Emerging Leader Awardee, will investigate "synthetic torpor"—inducing a hibernation-like state to globally suppress metabolism. The goal? Starve tumors while sparing healthy tissue. ❄️🧬 @cshlnews.bsky.social
Learn more about her work: themarkfoundation.org/portfolio/sp...
Spatiotemporal Profiling of the Aged Microenvironment in Tumor Dormancy and Recurrent Disease | The Mark Foundation for Cancer Research
Cancer recurrence can manifest more than a decade after the initial diagnosis and remission, and the local immune microenvironment of the target organ is a pivotal factor influencing the persistence…
themarkfoundation.org
December 15, 2025 at 9:24 PM
Learn more about her work: themarkfoundation.org/portfolio/sp...
The breakthrough builds on work Paul Thomas conducted through a ASPIRE Award granted in partnership with the Fibrolamellar Cancer Foundation. It offers new hope for FLC patients — and a new path forward for therapeutic vaccines targeting so-called “undruggable” cancer drivers.
December 4, 2025 at 9:07 PM
The breakthrough builds on work Paul Thomas conducted through a ASPIRE Award granted in partnership with the Fibrolamellar Cancer Foundation. It offers new hope for FLC patients — and a new path forward for therapeutic vaccines targeting so-called “undruggable” cancer drivers.